Loss of AZGP1 expression is a biomarker associated with progression to castration resistance, development of metastasis, and poor disease-specific survival in prostate cancer. However, high expression of AZGP1 cells in prostate cancer has been reported to increase proliferation and invasion.
The exact role of AZGP1 in prostate cancer progression remains elusive.
AZGP1 knockout and overexpressing prostate cancer cells were generated using a lentiviral system. The effects of AZGP1 under- or over-expression in prostate cancer cells were evaluated by in vitro cell proliferation, migration, and invasion assays. Heterozygous AZGP1± mice were obtained from European Mouse Mutant Archive (EMMA), and prostate tissues from homozygous knockout male mice were collected at 2, 6 and 10 months for histological analysis. In vivo xenografts generated from AZGP1 under- or over-expressing prostate cancer cells were used to determine the role of AZGP1 in prostate cancer tumor growth, and subsequent proteomics analysis was conducted to elucidate the mechanisms of AZGP1 action in prostate cancer progression. AZGP1 expression and microvessel density were measured in human prostate cancer samples on a tissue microarray of 215 independent patient samples.
Neither the knockout nor overexpression of AZGP1 exhibited significant effects on prostate cancer cell proliferation, clonal growth, migration, or invasion in vitro. The prostates of AZGP1-/- mice initially appeared to have grossly normal morphology; however, we observed fibrosis in the periglandular stroma and higher blood vessel density in the mouse prostate by 6 months. In PC3 and DU145 mouse xenografts, over-expression of AZGP1 did not affect tumor growth. Instead, these tumors displayed decreased microvessel density compared to xenografts derived from PC3 and DU145 control cells, suggesting that AZGP1 functions to inhibit angiogenesis in prostate cancer. Proteomics profiling further indicated that, compared to control xenografts, AZGP1 overexpressing PC3 xenografts are enriched with angiogenesis pathway proteins, including YWHAZ, EPHA2, SERPINE1, and PDCD6, MMP9, GPX1, HSPB1, COL18A1, RNH1, and ANXA1. In vitro functional studies show that AZGP1 inhibits human umbilical vein endothelial cell proliferation, migration, tubular formation and branching. Additionally, tumor microarray analysis shows that AZGP1 expression is negatively correlated with blood vessel density in human prostate cancer tissues.
AZGP1 is a negative regulator of angiogenesis, such that loss of AZGP1 promotes angiogenesis in prostate cancer. AZGP1 likely exerts heterotypical effects on cells in the tumor microenvironment, such as stromal and endothelial cells. This study sheds light on the anti-angiogenic characteristics of AZGP1 in the prostate and provides a rationale to target AZGP1 to inhibit prostate cancer progression.
Journal of translational medicine. 2024 Apr 24*** epublish ***
Ru M Wen, Zhengyuan Qiu, G Edward W Marti, Eric E Peterson, Fernando Jose Garcia Marques, Abel Bermudez, Yi Wei, Rosalie Nolley, Nathan Lam, Alex LaPat Polasko, Chun-Lung Chiu, Dalin Zhang, Sanghee Cho, Grigorios Marios Karageorgos, Elizabeth McDonough, Chrystal Chadwick, Fiona Ginty, Kyeong Joo Jung, Raghu Machiraju, Parag Mallick, Laura Crowley, Jonathan R Pollack, Hongjuan Zhao, Sharon J Pitteri, James D Brooks
Department of Urology, Stanford University School of Medicine, Stanford, CA, 94305, USA. ., Department of Urology, Stanford University School of Medicine, Stanford, CA, 94305, USA., Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, 94305, USA., Department of Radiology, Stanford University School of Medicine, Stanford, CA, 94305, USA., GE HealthCare Technology and Innovation Center, Niskayuna, NY, 12309, USA., Department of Computer Science and Engineering, The Ohio State University, Columbus, OH, 43210, USA., Canary Center at Stanford for Cancer Early Detection, Stanford University School of Medicine, Stanford, CA, 94305, USA., Department of Biochemistry, Stanford University School of Medicine, Stanford, CA, 94305, USA., Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA., Department of Urology, Stanford University School of Medicine, Stanford, CA, 94305, USA. .
PubMed http://www.ncbi.nlm.nih.gov/pubmed/38659028